VEGFA and non-small cell lung carcinoma: Bevacizumab, an anti-VEGF monoclonal antibody, was one of the first approved targeted therapies for non-squamous NSCLC nearly two decades ago, in combination with carboplatin plus paclitaxel chemotherapy [15].